Is Integra LifeSciences (IART) overvalued or fairly valued?

MarketChacha shows Integra LifeSciences's valuation in context — a forward P/E of about 7.0, a price-to-book of about 1.4 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Integra LifeSciences's revenue?

Integra LifeSciences reported revenue of $1.6B for FY2025, with net profit of $-516.5M, per official filings.

What is the share price of Integra LifeSciences (IART)?

Integra LifeSciences last traded at $17.66 (-3.2% on the day), as of 8/17/2026 — a delayed quote shown for education, not investment advice.

Integra LifeSciences

IART · NYSE · Healthcare · United States

Snapshot

TickerIART

ExchangeNYSE

SectorHealthcare

IndustryMedical Devices

CountryUnited States

Employees4,427

HeadquartersPrinceton, United States

Websitewww.integralife.com

Filings tracked14

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Who owns it

Insiders14.3%
Institutions85.7%
Public & other0.0%

306 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.13.74%
Rubric Capital Management LP9.97%
Vanguard Portfolio Management LLC4.81%
Morgan Stanley4.62%
Invesco Ltd.4.48%
Fuller & Thaler Asset Management Inc.4.42%
Paradigm Capital Management4.42%
State Street Corporation3.79%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 36.0 points over the period — profitability is trending down.

Net margin trend4.4% → -31.6%

Margin has compressed by about 36.0 points over the period — profitability is trending down.

Return on equity-49.5%

Latest ROE of -49.5% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $447.4M · EPS 0.80

Est. earnings growth -3.2%

Next fiscal year

Rev $1.7B · EPS 2.61

Est. earnings growth +6.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$1.6B

Net margin

-31.6%

ROE

-49.5%

Revenue CAGR (2y)

+3.0%

EPS (FY2025)

-6.74

Net profit (FY2025)

$-516.5M

Ask MarketChacha about IART

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$1.6B	$-516.5M	-6.74	-31.6%	-49.5%
FY2024	$1.6B	$-6.9M	-0.09	-0.4%	-0.4%
FY2023	$1.5B	$67.7M	0.84	4.4%	4.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$418.8M	$4.5M	0.06	1.1%
2026Q1	$391.9M	$-4.6M	-0.06	-1.2%
2025Q3	$402.1M	$-5.4M	-0.07	-1.3%
2025Q2	$415.6M	$-484.1M	-6.31	-116.5%
2025Q1	$382.7M	$-25.3M	-0.33	-6.6%
2024Q3	$380.8M	$-10.7M	-0.14	-2.8%
2024Q2	$418.2M	$-12.4M	-0.16	-3.0%
2024Q1	$368.9M	$-3.3M	-0.04	-0.9%
2023Q3	$382.4M	$19.5M	0.24	5.1%
2023Q2	$381.3M	$4.2M	0.05	1.1%
2023Q1	$380.8M	$24.2M	0.29	6.4%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC7/29/2026
8-K — Results of operations, Exhibits
SEC7/29/2026material
8-K — Executive/director change, Shareholder vote results, Exhibits
SEC5/8/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
8-K — Executive/director change, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Material agreement
SEC4/15/2026material
8-K — Results of operations, Exhibits
SEC2/26/2026material
10-K filing
SEC2/26/2026

2025

8-K — Executive/director change, Exhibits
SEC12/12/2025material
8-K — Results of operations, Exhibits
SEC10/30/2025material
10-Q filing
SEC10/30/2025
8-K — Results of operations, Exhibits
SEC7/31/2025material
10-Q filing
SEC7/31/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.